ADC Therapeutics SA (ADCT) Q1 2026 Earnings Call Transcript

Why It Matters

The financing and accelerating trial enrollments position ADC Therapeutics to expand ZENLATA into earlier‑line lymphoma treatments, potentially unlocking significant revenue growth and market share.

Key Takeaways

• Q1 net product revenue $15.8M, down YoY
• GAAP net loss narrowed to $41M, $0.30 per share
• $60M private placement extends cash runway to 2028
• ZENLATA shows 98% response in follicular lymphoma trial
• LOTUS V/VII data 2026‑2027 could lift revenues dramatically

Pulse Analysis

The antibody‑drug conjugate (ADC) market is maturing as biotech firms leverage targeted cytotoxic payloads to address unmet oncology needs. ADC Therapeutics’ lead asset, ZENLATA, exemplifies this trend by combining a potent exatecan payload with a CD79b‑directed antibody, delivering deep remissions in diffuse large B‑cell lymphoma (DLBCL). As competitors race to launch next‑generation ADCs, ZENLATA’s differentiated safety profile and outpatient administration give it a strategic edge in both complex and broadly accessible treatment segments.

Clinical momentum is accelerating. Recent follicular lymphoma data revealed a 98% overall response rate and an 83.6% complete response rate, underscoring ZENLATA’s efficacy beyond its approved third‑line DLBCL indication. The Phase III LOTUS V trial, pairing ZENLATA with rituximab, and the bispecific‑focused LOTUS VII study are on track to deliver pivotal data in 2026. Positive outcomes could expand the drug’s label into second‑line settings, potentially boosting peak U.S. revenues to $600 million‑$1 billion, according to management’s modeling.

Financially, the $60 million PIPE strengthens the balance sheet, pushing cash reserves to roughly $292 million and extending the runway through 2028. This liquidity cushion enables continued investment in ZENLATA’s trial portfolio and the development of a PSMA‑targeted ADC, diversifying the pipeline. For investors, the combination of disciplined cost reductions, robust clinical readouts, and ample cash provides a compelling risk‑adjusted upside as the company seeks to capture a larger share of the growing ADC market.